UCB to acquire Neurona Therapeutics in up to $1.15bn deal
Global biopharmaceutical company UCB is acquiring clinical-stage biotherapeutics firm Neurona Therapeutics, signalling a continued appetite for strategic consolidation within the life sciences sector. The first half of 2026 is rapidly emerging as a highly active breakout period for mergers and acquisitions across the broader biopharmaceutical landscape. This transaction represents a significant capital deployment by UCB to strengthen its neurology pipeline…